Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

Similar articles for PubMed (Select 23472874)

1.

Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression.

Reinhardt P, Schmid B, Burbulla LF, Schöndorf DC, Wagner L, Glatza M, Höing S, Hargus G, Heck SA, Dhingra A, Wu G, Müller S, Brockmann K, Kluba T, Maisel M, Krüger R, Berg D, Tsytsyura Y, Thiel CS, Psathaki OE, Klingauf J, Kuhlmann T, Klewin M, Müller H, Gasser T, Schöler HR, Sterneckert J.

Cell Stem Cell. 2013 Mar 7;12(3):354-67. doi: 10.1016/j.stem.2013.01.008.

2.

LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress.

Nguyen HN, Byers B, Cord B, Shcheglovitov A, Byrne J, Gujar P, Kee K, Schüle B, Dolmetsch RE, Langston W, Palmer TD, Pera RR.

Cell Stem Cell. 2011 Mar 4;8(3):267-80. doi: 10.1016/j.stem.2011.01.013.

3.

Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutation.

Su YC, Qi X.

Hum Mol Genet. 2013 Nov 15;22(22):4545-61. doi: 10.1093/hmg/ddt301. Epub 2013 Jun 27.

4.

A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2.

Dusonchet J, Kochubey O, Stafa K, Young SM Jr, Zufferey R, Moore DJ, Schneider BL, Aebischer P.

J Neurosci. 2011 Jan 19;31(3):907-12. doi: 10.1523/JNEUROSCI.5092-10.2011.

5.

Progressive degeneration of human neural stem cells caused by pathogenic LRRK2.

Liu GH, Qu J, Suzuki K, Nivet E, Li M, Montserrat N, Yi F, Xu X, Ruiz S, Zhang W, Wagner U, Kim A, Ren B, Li Y, Goebl A, Kim J, Soligalla RD, Dubova I, Thompson J, Yates J 3rd, Esteban CR, Sancho-Martinez I, Izpisua Belmonte JC.

Nature. 2012 Nov 22;491(7425):603-7. doi: 10.1038/nature11557. Epub 2012 Oct 17.

6.

Modeling Parkinson's disease using induced pluripotent stem cells.

Byers B, Lee HL, Reijo Pera R.

Curr Neurol Neurosci Rep. 2012 Jun;12(3):237-42. doi: 10.1007/s11910-012-0270-y. Review.

7.

Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity.

Yao C, Johnson WM, Gao Y, Wang W, Zhang J, Deak M, Alessi DR, Zhu X, Mieyal JJ, Roder H, Wilson-Delfosse AL, Chen SG.

Hum Mol Genet. 2013 Jan 15;22(2):328-44. doi: 10.1093/hmg/dds431. Epub 2012 Oct 12.

8.

Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake.

Zhou H, Huang C, Tong J, Hong WC, Liu YJ, Xia XG.

Int J Biol Sci. 2011;7(6):753-61. Epub 2011 Jun 9.

9.

LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease.

Yao C, El Khoury R, Wang W, Byrd TA, Pehek EA, Thacker C, Zhu X, Smith MA, Wilson-Delfosse AL, Chen SG.

Neurobiol Dis. 2010 Oct;40(1):73-81. doi: 10.1016/j.nbd.2010.04.002. Epub 2010 Apr 9.

10.

(G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.

Chen CY, Weng YH, Chien KY, Lin KJ, Yeh TH, Cheng YP, Lu CS, Wang HL.

Cell Death Differ. 2012 Oct;19(10):1623-33. doi: 10.1038/cdd.2012.42. Epub 2012 Apr 27.

11.

LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study.

Sharma S, Bandopadhyay R, Lashley T, Renton AE, Kingsbury AE, Kumaran R, Kallis C, Vilariño-Güell C, O'Sullivan SS, Lees AJ, Revesz T, Wood NW, Holton JL.

Neuropathol Appl Neurobiol. 2011 Dec;37(7):777-90. doi: 10.1111/j.1365-2990.2011.01187.x.

PMID:
21696411
12.

Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway.

Carballo-Carbajal I, Weber-Endress S, Rovelli G, Chan D, Wolozin B, Klein CL, Patenge N, Gasser T, Kahle PJ.

Cell Signal. 2010 May;22(5):821-7. doi: 10.1016/j.cellsig.2010.01.006. Epub 2010 Jan 13.

13.

Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation.

Luzón-Toro B, Rubio de la Torre E, Delgado A, Pérez-Tur J, Hilfiker S.

Hum Mol Genet. 2007 Sep 1;16(17):2031-9. Epub 2007 Jun 20.

14.

Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease.

Huang L, Shimoji M, Wang J, Shah S, Kamila S, Biehl ER, Lim S, Chang A, Maguire-Zeiss KA, Su X, Federoff HJ.

Neurotherapeutics. 2013 Oct;10(4):840-51. doi: 10.1007/s13311-013-0208-3.

15.

A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.

Illarioshkin SN, Shadrina MI, Slominsky PA, Bespalova EV, Zagorovskaya TB, Bagyeva GKh, Markova ED, Limborska SA, Ivanova-Smolenskaya IA.

Eur J Neurol. 2007 Apr;14(4):413-7.

PMID:
17388990
16.

LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction.

Sanders LH, Laganière J, Cooper O, Mak SK, Vu BJ, Huang YA, Paschon DE, Vangipuram M, Sundararajan R, Urnov FD, Langston JW, Gregory PD, Zhang HS, Greenamyre JT, Isacson O, Schüle B.

Neurobiol Dis. 2014 Feb;62:381-6. doi: 10.1016/j.nbd.2013.10.013. Epub 2013 Oct 19.

17.

Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells.

Plowey ED, Cherra SJ 3rd, Liu YJ, Chu CT.

J Neurochem. 2008 May;105(3):1048-56. doi: 10.1111/j.1471-4159.2008.05217.x. Epub 2008 Jan 7.

18.

Parkinson's disease in a dish - Using stem cells as a molecular tool.

Badger JL, Cordero-Llana O, Hartfield EM, Wade-Martins R.

Neuropharmacology. 2014 Jan;76 Pt A:88-96. doi: 10.1016/j.neuropharm.2013.08.035. Epub 2013 Sep 10. Review.

PMID:
24035919
19.

G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization.

Papkovskaia TD, Chau KY, Inesta-Vaquera F, Papkovsky DB, Healy DG, Nishio K, Staddon J, Duchen MR, Hardy J, Schapira AH, Cooper JM.

Hum Mol Genet. 2012 Oct 1;21(19):4201-13. doi: 10.1093/hmg/dds244. Epub 2012 Jun 26.

20.

The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.

Thaler A, Ash E, Gan-Or Z, Orr-Urtreger A, Giladi N.

J Neural Transm. 2009 Nov;116(11):1473-82. doi: 10.1007/s00702-009-0303-0. Review.

PMID:
19756366
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk